GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSNW) » Definitions » Other Income (Minority Interest)

NeuroSense Therapeutics (NeuroSense Therapeutics) Other Income (Minority Interest) : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Other Income (Minority Interest)?

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary. NeuroSense Therapeutics's Other Income (Minority Interest) for the three months ended in Dec. 2023 was $0.00 Mil. Its Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.


NeuroSense Therapeutics Other Income (Minority Interest) Historical Data

The historical data trend for NeuroSense Therapeutics's Other Income (Minority Interest) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics Other Income (Minority Interest) Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Minority Interest)
- - - - -

NeuroSense Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Income (Minority Interest) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NeuroSense Therapeutics Other Income (Minority Interest) Calculation

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary.

Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuroSense Therapeutics  (NAS:NRSNW) Other Income (Minority Interest) Explanation

Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company. It is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Traded in Other Exchanges
Address
11 HaMenofim Street, Building B, Herzliya, ISR, 4676670
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.